PCDHGA11 and central nervous system cancer: Their results show that 82% of grade II astrocytomas, 80% of grade III astrocytomas and 74% of WHO grade IV gliomas showed non- or low expression of PCDHGA11 compared to the average of five normal brain tissue samples.